Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Its principal development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and a program for an undisclosed rare disease. The company's development programs also comprise additional rare disease programs and various programs targeting undisclosed targets in chronic liver diseases and cardiovascular diseases, as well as a program for the treatment of hypercholesterolemia. The company has collaborative research and license agreement with Boehringer Ingelheim International GmbH; research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd., and Eli Lilly and Company; collaboration with Alexion Pharmaceuticals, Inc.; and license agreement with City of Hope. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-621-8097
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$6.18 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/13/2019 (Estimated)
OptionableOptionable
Dicerna Pharmaceuticals (NASDAQ:DRNA) Frequently Asked Questions
What is Dicerna Pharmaceuticals' stock symbol?
Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."
How were Dicerna Pharmaceuticals' earnings last quarter?
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) announced its earnings results on Monday, March, 11th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.06. The biopharmaceutical company had revenue of $1.54 million for the quarter, compared to analyst estimates of $8.38 million. Dicerna Pharmaceuticals had a negative return on equity of 53.27% and a negative net margin of 1,438.68%. View Dicerna Pharmaceuticals' Earnings History.
When is Dicerna Pharmaceuticals' next earnings date?
What price target have analysts set for DRNA?
9 analysts have issued twelve-month price objectives for Dicerna Pharmaceuticals' shares. Their forecasts range from $17.00 to $30.00. On average, they expect Dicerna Pharmaceuticals' share price to reach $22.8750 in the next year. This suggests a possible upside of 72.1% from the stock's current price. View Analyst Price Targets for Dicerna Pharmaceuticals.
What is the consensus analysts' recommendation for Dicerna Pharmaceuticals?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dicerna Pharmaceuticals.
Has Dicerna Pharmaceuticals been receiving favorable news coverage?
Headlines about DRNA stock have been trending somewhat negative this week, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Dicerna Pharmaceuticals earned a media sentiment score of -1.1 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future.
Who are some of Dicerna Pharmaceuticals' key competitors?
Some companies that are related to Dicerna Pharmaceuticals include Agios Pharmaceuticals (AGIO), Blueprint Medicines (BPMC), Ultragenyx Pharmaceutical (RARE), Intercept Pharmaceuticals (ICPT), Amicus Therapeutics (FOLD), Global Blood Therapeutics (GBT), Mirati Therapeutics (MRTX), Reata Pharmaceuticals (RETA), Ligand Pharmaceuticals (LGND), Akcea Therapeutics (AKCA), Emergent Biosolutions (EBS), Uniqure (QURE), Biohaven Pharmaceutical (BHVN), Zogenix (ZGNX) and PTC Therapeutics (PTCT).
What other stocks do shareholders of Dicerna Pharmaceuticals own?
Who are Dicerna Pharmaceuticals' key executives?
Dicerna Pharmaceuticals' management team includes the folowing people:
- Dr. Douglas M. Fambrough III, Co-Founder, CEO, Pres & Director (Age 50)
- Dr. Bob D. Brown, Chief Scientific Officer & Sr. VP (Age 54)
- Dr. Ralf H. Rosskamp, Chief Medical Officer (Age 66)
- Dr. Mark Behlke, Co-Founder & Member of Scientific Advisory Board
- Prof. John J. Rossi, Co-Founder & Chairman of Scientific Advisory Board (Age 72)
Who are Dicerna Pharmaceuticals' major shareholders?
Dicerna Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include RTW Investments LP (9.42%), BlackRock Inc. (6.90%), RA Capital Management LLC (3.92%), FMR LLC (1.76%), Emerald Advisers LLC (1.61%) and Emerald Mutual Fund Advisers Trust (1.44%). Company insiders that own Dicerna Pharmaceuticals stock include Bain Capital Life Sciences Inv, Brian K Halak, Dennis Langer and James B Weissman. View Institutional Ownership Trends for Dicerna Pharmaceuticals.
Which institutional investors are selling Dicerna Pharmaceuticals stock?
DRNA stock was sold by a variety of institutional investors in the last quarter, including RA Capital Management LLC, Two Sigma Advisers LP, Squarepoint Ops LLC, MetLife Investment Advisors LLC, Eversept Partners LP, FMR LLC, New York State Common Retirement Fund and Emerald Mutual Fund Advisers Trust. Company insiders that have sold Dicerna Pharmaceuticals company stock in the last year include Brian K Halak, Dennis Langer and James B Weissman. View Insider Buying and Selling for Dicerna Pharmaceuticals.
Which institutional investors are buying Dicerna Pharmaceuticals stock?
DRNA stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., RTW Investments LP, Emory University, Candriam Luxembourg S.C.A., Citigroup Inc., Fosun International Ltd, Geode Capital Management LLC and Geode Capital Management LLC. View Insider Buying and Selling for Dicerna Pharmaceuticals.
How do I buy shares of Dicerna Pharmaceuticals?
Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dicerna Pharmaceuticals' stock price today?
One share of DRNA stock can currently be purchased for approximately $13.29.
How big of a company is Dicerna Pharmaceuticals?
Dicerna Pharmaceuticals has a market capitalization of $907.24 million and generates $6.18 million in revenue each year. The biopharmaceutical company earns $-88,850,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis.
What is Dicerna Pharmaceuticals' official website?
How can I contact Dicerna Pharmaceuticals?
Dicerna Pharmaceuticals' mailing address is 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA, 02140. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]
MarketBeat Community Rating for Dicerna Pharmaceuticals (NASDAQ DRNA)
MarketBeat's community ratings are surveys of what our community members think about Dicerna Pharmaceuticals and other stocks. Vote "Outperform" if you believe DRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
